Share Price and Basic Stock Data
Last Updated: October 22, 2025, 8:24 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Chemiesynth (Vapi) Ltd, operating in the chemicals sector, has shown fluctuations in its revenue over the years. For the fiscal year ending March 2023, the company reported sales of ₹20.94 Cr, a decline from ₹30.18 Cr in the previous year. However, the trailing twelve months (TTM) figure stood at ₹20.00 Cr, indicating some stabilization. Sales trends have varied quarterly, with the highest revenue recorded in December 2022 at ₹7.12 Cr, while the lowest was in December 2023 at ₹3.22 Cr. This inconsistency suggests challenges in maintaining steady demand or operational efficiency. The company’s operating profit margin (OPM) has hovered around 12.13% recently, reflecting its ability to manage costs relative to sales. Overall, Chemiesynth’s revenue trajectory highlights both volatility and potential opportunities for growth, especially if it can capitalize on market demands effectively.
Profitability and Efficiency Metrics
The profitability of Chemiesynth (Vapi) Ltd remains a mixed bag, with its net profit recorded at -₹0.32 Cr for the latest fiscal year. This marks a significant decline compared to previous years when net profits were positive, notably ₹2.72 Cr in FY 2022. The company’s return on equity (ROE) stood at 0.99%, indicating a struggle to generate adequate returns for shareholders. Furthermore, the return on capital employed (ROCE) was reported at 3.10%, which is relatively low compared to typical sector performance. The interest coverage ratio (ICR) of 2.75x suggests that the company can comfortably cover interest expenses, but the overall profitability metrics raise concerns. The operating profit margin (OPM) of 12.13% is commendable but indicates that there is room for improvement in cost management to enhance profitability further.
Balance Sheet Strength and Financial Ratios
Chemiesynth’s balance sheet reflects a somewhat precarious financial position, with total borrowings at ₹15.02 Cr against reserves of ₹7.91 Cr. This results in a debt-to-equity ratio of 1.37x, indicating a reliance on debt financing, which could pose risks during economic downturns. The current ratio stands at 0.46, suggesting liquidity issues, while the quick ratio further declines to 0.30, highlighting potential challenges in meeting short-term obligations. The company’s book value per share is reported at ₹35.77, which, when compared to its current share price of ₹37.6, results in a price-to-book value ratio of 0.95x. This valuation suggests that the stock is trading near its book value, which might attract value investors. However, the overall financial ratios indicate a need for strategic financial management to improve the company’s capital structure and liquidity.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chemiesynth (Vapi) Ltd shows a significant promoter holding of 62.35%, which reflects strong management control and commitment to the company. The public holds the remaining 37.65%, with the total number of shareholders recorded at 524. This concentrated ownership structure may instill confidence among investors regarding the company’s long-term vision, although it could also deter broader market participation. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) indicates a lack of institutional interest, which could be a concern for potential investors looking for validation from larger entities. The stability in promoter holding over recent quarters suggests confidence in the company’s future, yet the lack of institutional backing raises questions about market perceptions and the company’s growth prospects.
Outlook, Risks, and Final Insight
The outlook for Chemiesynth (Vapi) Ltd hinges on its ability to stabilize revenue and improve profitability metrics. Risks include high leverage with a debt-to-equity ratio of 1.37, which may impact financial flexibility, and ongoing liquidity challenges as evidenced by low current and quick ratios. Additionally, the company’s history of fluctuating sales and profits could deter potential investors. However, the strong promoter stake and improving operational margins provide a foundation for potential recovery. If Chemiesynth can enhance operational efficiency and manage debt levels effectively, it may attract more investor interest. Conversely, failure to address these financial concerns could lead to further declines in shareholder confidence and market performance. The company’s ability to navigate these challenges will be crucial for its future trajectory and overall viability in the competitive chemicals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chemiesynth (Vapi) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 124 Cr. | 348 | 458/255 | 128 | 390 | 0.03 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,648 Cr. | 9,648 | 14,284/8,150 | 57.5 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 37.9 Cr. | 126 | 329/114 | 15.3 | 24.9 | 0.79 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 35.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 260 Cr. | 325 | 385/160 | 20.1 | 94.6 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,428.00 Cr | 1,667.80 | 402.50 | 327.18 | 0.36% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.54 | 4.43 | 7.12 | 4.85 | 4.39 | 4.37 | 3.22 | 4.45 | 2.85 | 5.47 | 3.88 | 6.68 |
| Expenses | 4.76 | 3.94 | 5.78 | 3.89 | 4.48 | 3.00 | 3.31 | 4.10 | 2.66 | 4.51 | 3.65 | 5.87 |
| Operating Profit | -0.22 | 0.49 | 1.34 | 0.96 | -0.09 | 1.37 | -0.09 | 0.35 | 0.19 | 0.96 | 0.23 | 0.81 |
| OPM % | -4.85% | 11.06% | 18.82% | 19.79% | -2.05% | 31.35% | -2.80% | 7.87% | 6.67% | 17.55% | 5.93% | 12.13% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest | 0.11 | 0.16 | 0.15 | 0.16 | 0.12 | 0.21 | 0.11 | 0.26 | 0.09 | 0.17 | 0.34 | 0.20 |
| Depreciation | 0.27 | 0.27 | 0.30 | 0.33 | 0.30 | 0.32 | 0.32 | 0.36 | 0.34 | 0.38 | 0.36 | 0.33 |
| Profit before tax | -0.60 | 0.06 | 0.89 | 0.47 | -0.51 | 0.84 | -0.52 | -0.26 | -0.24 | 0.41 | -0.47 | 0.29 |
| Tax % | 0.00% | 0.00% | 5.62% | 44.68% | 0.00% | 0.00% | 0.00% | -23.08% | 0.00% | 0.00% | 0.00% | 34.48% |
| Net Profit | -0.61 | 0.06 | 0.84 | 0.26 | -0.51 | 0.85 | -0.52 | -0.20 | -0.24 | 0.42 | -0.47 | 0.19 |
| EPS in Rs | -1.99 | 0.20 | 2.74 | 0.85 | -1.66 | 2.77 | -1.69 | -0.65 | -0.78 | 1.37 | -1.53 | 0.62 |
Last Updated: May 31, 2025, 6:32 am
Below is a detailed analysis of the quarterly data for Chemiesynth (Vapi) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 6.68 Cr.. The value appears strong and on an upward trend. It has increased from 3.88 Cr. (Dec 2024) to 6.68 Cr., marking an increase of 2.80 Cr..
- For Expenses, as of Mar 2025, the value is 5.87 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.65 Cr. (Dec 2024) to 5.87 Cr., marking an increase of 2.22 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.23 Cr. (Dec 2024) to 0.81 Cr., marking an increase of 0.58 Cr..
- For OPM %, as of Mar 2025, the value is 12.13%. The value appears strong and on an upward trend. It has increased from 5.93% (Dec 2024) to 12.13%, marking an increase of 6.20%.
- For Other Income, as of Mar 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Dec 2024) to 0.01 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.20 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.34 Cr. (Dec 2024) to 0.20 Cr., marking a decrease of 0.14 Cr..
- For Depreciation, as of Mar 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.36 Cr. (Dec 2024) to 0.33 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.29 Cr.. The value appears strong and on an upward trend. It has increased from -0.47 Cr. (Dec 2024) to 0.29 Cr., marking an increase of 0.76 Cr..
- For Tax %, as of Mar 2025, the value is 34.48%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Dec 2024) to 34.48%, marking an increase of 34.48%.
- For Net Profit, as of Mar 2025, the value is 0.19 Cr.. The value appears strong and on an upward trend. It has increased from -0.47 Cr. (Dec 2024) to 0.19 Cr., marking an increase of 0.66 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.62. The value appears strong and on an upward trend. It has increased from -1.53 (Dec 2024) to 0.62, marking an increase of 2.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.63 | 11.13 | 5.12 | 3.09 | 13.32 | 11.20 | 14.56 | 19.90 | 30.18 | 20.94 | 16.43 | 18.89 | 20.00 |
| Expenses | 9.10 | 11.55 | 5.26 | 3.17 | 12.67 | 9.26 | 12.27 | 14.32 | 25.71 | 18.37 | 14.88 | 16.68 | 17.82 |
| Operating Profit | 0.53 | -0.42 | -0.14 | -0.08 | 0.65 | 1.94 | 2.29 | 5.58 | 4.47 | 2.57 | 1.55 | 2.21 | 2.18 |
| OPM % | 5.50% | -3.77% | -2.73% | -2.59% | 4.88% | 17.32% | 15.73% | 28.04% | 14.81% | 12.27% | 9.43% | 11.70% | 10.90% |
| Other Income | 0.13 | 0.02 | 0.03 | 0.27 | 0.46 | 0.06 | 0.12 | 0.02 | 0.94 | 0.00 | 0.01 | 0.01 | 0.01 |
| Interest | 0.30 | 0.29 | 0.23 | 0.19 | 0.19 | 0.09 | 0.28 | 0.48 | 0.50 | 0.59 | 0.71 | 0.83 | 0.96 |
| Depreciation | 0.25 | 0.28 | 0.20 | 0.18 | 0.52 | 0.46 | 0.55 | 0.78 | 1.05 | 1.17 | 1.30 | 1.40 | 1.46 |
| Profit before tax | 0.11 | -0.97 | -0.54 | -0.18 | 0.40 | 1.45 | 1.58 | 4.34 | 3.86 | 0.81 | -0.45 | -0.01 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 19.31% | 17.09% | 17.74% | 29.79% | 32.10% | -13.33% | 1,000.00% | |
| Net Profit | 0.11 | -0.97 | -0.54 | -0.18 | 0.39 | 1.17 | 1.31 | 3.56 | 2.72 | 0.56 | -0.39 | -0.11 | -0.32 |
| EPS in Rs | 0.36 | -3.16 | -1.76 | -0.59 | 1.27 | 3.81 | 4.27 | 11.60 | 8.86 | 1.82 | -1.27 | -0.36 | -1.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -981.82% | 44.33% | 66.67% | 316.67% | 200.00% | 11.97% | 171.76% | -23.60% | -79.41% | -169.64% | 71.79% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1026.15% | 22.34% | 250.00% | -116.67% | -188.03% | 159.79% | -195.35% | -55.82% | -90.23% | 241.44% |
Chemiesynth (Vapi) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | -14% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -191% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 0% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: July 25, 2025, 1:35 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 |
| Reserves | 0.70 | -0.28 | -0.82 | -1.05 | -0.66 | 0.52 | 1.83 | 5.39 | 8.10 | 8.66 | 8.27 | 7.91 |
| Borrowings | 6.46 | 6.70 | 8.17 | 8.02 | 8.01 | 7.69 | 9.73 | 10.86 | 11.60 | 13.63 | 15.54 | 15.02 |
| Other Liabilities | 3.00 | 2.74 | 1.27 | 1.58 | 1.48 | 3.59 | 3.18 | 7.55 | 6.86 | 5.65 | 4.49 | 6.19 |
| Total Liabilities | 13.23 | 12.23 | 11.69 | 11.62 | 11.90 | 14.87 | 17.81 | 26.87 | 29.63 | 31.01 | 31.37 | 32.19 |
| Fixed Assets | 10.41 | 10.09 | 9.98 | 9.71 | 9.62 | 10.69 | 12.31 | 20.39 | 22.38 | 24.51 | 25.08 | 25.83 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 1.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2.82 | 2.14 | 1.71 | 1.91 | 2.28 | 3.94 | 4.16 | 6.48 | 7.25 | 6.50 | 6.29 | 6.36 |
| Total Assets | 13.23 | 12.23 | 11.69 | 11.62 | 11.90 | 14.87 | 17.81 | 26.87 | 29.63 | 31.01 | 31.37 | 32.19 |
Below is a detailed analysis of the balance sheet data for Chemiesynth (Vapi) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 3.07 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.07 Cr..
- For Reserves, as of Mar 2025, the value is 7.91 Cr.. The value appears to be declining and may need further review. It has decreased from 8.27 Cr. (Mar 2024) to 7.91 Cr., marking a decrease of 0.36 Cr..
- For Borrowings, as of Mar 2025, the value is 15.02 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 15.54 Cr. (Mar 2024) to 15.02 Cr., marking a decrease of 0.52 Cr..
- For Other Liabilities, as of Mar 2025, the value is 6.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.49 Cr. (Mar 2024) to 6.19 Cr., marking an increase of 1.70 Cr..
- For Total Liabilities, as of Mar 2025, the value is 32.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 31.37 Cr. (Mar 2024) to 32.19 Cr., marking an increase of 0.82 Cr..
- For Fixed Assets, as of Mar 2025, the value is 25.83 Cr.. The value appears strong and on an upward trend. It has increased from 25.08 Cr. (Mar 2024) to 25.83 Cr., marking an increase of 0.75 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 6.36 Cr.. The value appears strong and on an upward trend. It has increased from 6.29 Cr. (Mar 2024) to 6.36 Cr., marking an increase of 0.07 Cr..
- For Total Assets, as of Mar 2025, the value is 32.19 Cr.. The value appears strong and on an upward trend. It has increased from 31.37 Cr. (Mar 2024) to 32.19 Cr., marking an increase of 0.82 Cr..
However, the Borrowings (15.02 Cr.) are higher than the Reserves (7.91 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.93 | -7.12 | -8.31 | -8.10 | -7.36 | -5.75 | -7.44 | -5.28 | -7.13 | -11.06 | -13.99 | -12.81 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.51 | 26.89 | 31.37 | 24.81 | 27.13 | 55.08 | 39.86 | 67.86 | 41.60 | 47.24 | 47.10 | 55.07 |
| Inventory Days | 126.69 | 44.60 | 136.35 | 580.41 | 16.18 | 231.23 | 217.06 | 165.17 | 80.99 | 200.09 | 386.19 | 167.61 |
| Days Payable | 156.86 | 126.75 | 159.43 | 741.97 | 43.60 | 605.79 | 366.21 | 695.35 | 159.36 | 200.78 | 111.85 | 201.64 |
| Cash Conversion Cycle | -17.66 | -55.26 | 8.29 | -136.75 | -0.29 | -319.48 | -109.29 | -462.31 | -36.77 | 46.55 | 321.44 | 21.04 |
| Working Capital Days | -48.89 | -53.78 | -47.76 | -103.95 | -9.04 | -28.68 | -60.92 | -65.85 | -49.83 | -65.89 | -105.08 | -122.12 |
| ROCE % | 3.04% | -6.90% | -3.21% | -2.44% | 5.28% | 13.73% | 13.89% | 28.39% | 16.35% | 5.82% | 1.00% | 3.10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.35 | -1.26 | 1.81 | 8.85 | 11.60 |
| Diluted EPS (Rs.) | -0.35 | -1.26 | 1.81 | 8.85 | 11.60 |
| Cash EPS (Rs.) | 4.22 | 2.97 | 5.61 | 12.28 | 14.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 35.77 | 36.94 | 38.20 | 36.39 | 27.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 35.77 | 36.94 | 38.20 | 36.39 | 27.55 |
| Revenue From Operations / Share (Rs.) | 61.52 | 53.53 | 68.21 | 98.32 | 64.81 |
| PBDIT / Share (Rs.) | 7.14 | 5.04 | 8.34 | 14.58 | 18.03 |
| PBIT / Share (Rs.) | 2.57 | 0.80 | 4.54 | 11.15 | 15.49 |
| PBT / Share (Rs.) | -0.02 | -1.47 | 2.65 | 12.57 | 14.12 |
| Net Profit / Share (Rs.) | -0.34 | -1.26 | 1.81 | 8.85 | 11.60 |
| PBDIT Margin (%) | 11.60 | 9.41 | 12.22 | 14.83 | 27.82 |
| PBIT Margin (%) | 4.18 | 1.50 | 6.65 | 11.33 | 23.90 |
| PBT Margin (%) | -0.04 | -2.74 | 3.88 | 12.78 | 21.78 |
| Net Profit Margin (%) | -0.56 | -2.36 | 2.65 | 8.99 | 17.89 |
| Return on Networth / Equity (%) | -0.96 | -3.42 | 4.73 | 24.30 | 42.11 |
| Return on Capital Employeed (%) | 3.87 | 1.16 | 6.50 | 17.22 | 26.86 |
| Return On Assets (%) | -0.32 | -1.23 | 1.79 | 9.16 | 13.25 |
| Long Term Debt / Equity (X) | 0.73 | 0.75 | 0.71 | 0.67 | 1.07 |
| Total Debt / Equity (X) | 1.37 | 1.37 | 1.16 | 1.04 | 1.28 |
| Asset Turnover Ratio (%) | 0.59 | 0.52 | 0.69 | 1.07 | 0.89 |
| Current Ratio (X) | 0.46 | 0.53 | 0.60 | 0.68 | 0.65 |
| Quick Ratio (X) | 0.30 | 0.21 | 0.30 | 0.45 | 0.49 |
| Inventory Turnover Ratio (X) | 1.08 | 1.11 | 2.48 | 5.82 | 2.02 |
| Interest Coverage Ratio (X) | 2.75 | 2.22 | 4.41 | 9.33 | 13.16 |
| Interest Coverage Ratio (Post Tax) (X) | 0.86 | 0.44 | 1.96 | 4.75 | 9.46 |
| Enterprise Value (Cr.) | 25.47 | 23.72 | 19.75 | 16.16 | 0.00 |
| EV / Net Operating Revenue (X) | 1.35 | 1.44 | 0.94 | 0.53 | 0.00 |
| EV / EBITDA (X) | 11.62 | 15.33 | 7.71 | 3.61 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.55 | 0.50 | 0.29 | 0.18 | 0.00 |
| Price / BV (X) | 0.95 | 0.72 | 0.52 | 0.49 | 0.00 |
| Price / Net Operating Revenue (X) | 0.55 | 0.50 | 0.29 | 0.18 | 0.00 |
| EarningsYield | -0.01 | -0.04 | 0.09 | 0.48 | 0.00 |
After reviewing the key financial ratios for Chemiesynth (Vapi) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has increased from -1.26 (Mar 24) to -0.35, marking an increase of 0.91.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has increased from -1.26 (Mar 24) to -0.35, marking an increase of 0.91.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.22. This value is within the healthy range. It has increased from 2.97 (Mar 24) to 4.22, marking an increase of 1.25.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 35.77. It has decreased from 36.94 (Mar 24) to 35.77, marking a decrease of 1.17.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 35.77. It has decreased from 36.94 (Mar 24) to 35.77, marking a decrease of 1.17.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.52. It has increased from 53.53 (Mar 24) to 61.52, marking an increase of 7.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.14. This value is within the healthy range. It has increased from 5.04 (Mar 24) to 7.14, marking an increase of 2.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.57. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.57, marking an increase of 1.77.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 0. It has increased from -1.47 (Mar 24) to -0.02, marking an increase of 1.45.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.34. This value is below the healthy minimum of 2. It has increased from -1.26 (Mar 24) to -0.34, marking an increase of 0.92.
- For PBDIT Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 9.41 (Mar 24) to 11.60, marking an increase of 2.19.
- For PBIT Margin (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 10. It has increased from 1.50 (Mar 24) to 4.18, marking an increase of 2.68.
- For PBT Margin (%), as of Mar 25, the value is -0.04. This value is below the healthy minimum of 10. It has increased from -2.74 (Mar 24) to -0.04, marking an increase of 2.70.
- For Net Profit Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 5. It has increased from -2.36 (Mar 24) to -0.56, marking an increase of 1.80.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.96. This value is below the healthy minimum of 15. It has increased from -3.42 (Mar 24) to -0.96, marking an increase of 2.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.87. This value is below the healthy minimum of 10. It has increased from 1.16 (Mar 24) to 3.87, marking an increase of 2.71.
- For Return On Assets (%), as of Mar 25, the value is -0.32. This value is below the healthy minimum of 5. It has increased from -1.23 (Mar 24) to -0.32, marking an increase of 0.91.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.73. This value is within the healthy range. It has decreased from 0.75 (Mar 24) to 0.73, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.37. This value exceeds the healthy maximum of 1. There is no change compared to the previous period (Mar 24) which recorded 1.37.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has increased from 0.52 (Mar 24) to 0.59, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1.5. It has decreased from 0.53 (Mar 24) to 0.46, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.30, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 4. It has decreased from 1.11 (Mar 24) to 1.08, marking a decrease of 0.03.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 3. It has increased from 2.22 (Mar 24) to 2.75, marking an increase of 0.53.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 3. It has increased from 0.44 (Mar 24) to 0.86, marking an increase of 0.42.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25.47. It has increased from 23.72 (Mar 24) to 25.47, marking an increase of 1.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.35. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 11.62. This value is within the healthy range. It has decreased from 15.33 (Mar 24) to 11.62, marking a decrease of 3.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.50 (Mar 24) to 0.55, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has increased from 0.72 (Mar 24) to 0.95, marking an increase of 0.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.50 (Mar 24) to 0.55, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to -0.01, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemiesynth (Vapi) Ltd:
- Net Profit Margin: -0.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.87% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.96% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 402.5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.37
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Others | Plot No 27, GIDC, Vapi, Valsad District Gujarat 396195 | csl@chemiesynth.com http://www.chemiesynth.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sandip Satishbhai Zaveri | Managing Director |
| Mr. Satish Bhogilal Zaveri | Non Exe.Non Ind.Director |
| Mr. Bhanurai Nagindas Mehta | Non Exe.Non Ind.Director |
| Mr. Rushabh Suresh Mehta | Non Exe.Non Ind.Director |
| Mrs. Jigna Prajapati | Independent Woman Director |
| Mr. Pramod Gopaldas Gujarathi | Independent Director |
FAQ
What is the intrinsic value of Chemiesynth (Vapi) Ltd?
Chemiesynth (Vapi) Ltd's intrinsic value (as of 03 November 2025) is 4.34 which is 88.46% lower the current market price of 37.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 11.6 Cr. market cap, FY2025-2026 high/low of 37.6/35.8, reserves of ₹7.91 Cr, and liabilities of 32.19 Cr.
What is the Market Cap of Chemiesynth (Vapi) Ltd?
The Market Cap of Chemiesynth (Vapi) Ltd is 11.6 Cr..
What is the current Stock Price of Chemiesynth (Vapi) Ltd as on 03 November 2025?
The current stock price of Chemiesynth (Vapi) Ltd as on 03 November 2025 is 37.6.
What is the High / Low of Chemiesynth (Vapi) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemiesynth (Vapi) Ltd stocks is 37.6/35.8.
What is the Stock P/E of Chemiesynth (Vapi) Ltd?
The Stock P/E of Chemiesynth (Vapi) Ltd is .
What is the Book Value of Chemiesynth (Vapi) Ltd?
The Book Value of Chemiesynth (Vapi) Ltd is 35.8.
What is the Dividend Yield of Chemiesynth (Vapi) Ltd?
The Dividend Yield of Chemiesynth (Vapi) Ltd is 0.00 %.
What is the ROCE of Chemiesynth (Vapi) Ltd?
The ROCE of Chemiesynth (Vapi) Ltd is 3.10 %.
What is the ROE of Chemiesynth (Vapi) Ltd?
The ROE of Chemiesynth (Vapi) Ltd is 0.99 %.
What is the Face Value of Chemiesynth (Vapi) Ltd?
The Face Value of Chemiesynth (Vapi) Ltd is 10.0.